3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
4
Sarcoma
2
Lymphoid
2
Head & Neck
2
Genitourinary
2
Endocrine
2
Dermatologic
2
Thoracic
1
Other hematologic neoplasm
1
NET
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Thyroid Cancer, Papillary
1
Sarcoma
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
3
Fluorodeoxyglucose F18
2
FAPI-46
2
fluorodopa F 18
1
entrectinib
1
dactolisib
1
alectinib
1
Specimen Handling
1
Respiratory Therapy
1
Quality of Life
1
Positron-Emission Tomography
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Immunotherapy
1
Furosemide
1
Everolimus
1
Drug Therapy
1
Biological Therapy
1
4-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
entrectinib
×
NET
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA